A clinical systematic review is the most rigorous form of evidence synthesis in healthcare and biomedical research. It answers a specific, predefined clinical question by identifying, appraising, and synthesizing all eligible studies using explicit, reproducible methods. When conducted to standard, a clinical systematic review sits at Level I of the evidence hierarchy, above individual randomized controlled trials, because it pools evidence across multiple studies and formally accounts for variation and quality. When conducted poorly, it produces conclusions that mislead clinical practice, fail journal peer review, or get retracted.
This guide covers everything researchers need to understand, plan, and execute a clinical systematic review: the authoritative definitions, the specific characteristics that distinguish clinical reviews from other evidence synthesis types, the ten-stage process from PROSPERO registration to manuscript submission, the databases and tools required at each stage, and the journal standards at The Lancet, BMJ, JAMA, and Annals of Internal Medicine that determine whether a manuscript is accepted or returned.
Quick Answer:
A clinical systematic review is a structured, reproducible evidence synthesis that answers a pre-specified clinical question. It uses explicit search strategies across multiple databases, dual independent screening and data extraction, risk-of-bias assessment with validated tools such as RoB 2 or QUADAS-2, and certainty-of-evidence grading with GRADE. Reporting follows PRISMA 2020. Registration on PROSPERO is required before screening begins. The process typically runs 12 to 24 months from protocol to publication.
A clinical systematic review conducted to Cochrane standards sits at Level I of the evidence hierarchy. When it fails, at the search strategy, the GRADE assessment, or the PRISMA 2020 manuscript, it falls nowhere. ScribeLab Writer's systematic review service covers every stage from protocol to submission-ready manuscript, starting from $850 with a 2-4-hour scoped quote.
What Is a Clinical Systematic Review? Definitions From Authoritative Sources
Several major institutions have formally defined systematic reviews in the clinical context. The definitions converge on the same core elements, but each adds important clarification.
The Cochrane Collaboration, whose reviews represent the global benchmark for clinical evidence synthesis, defines a systematic review as one that "aims to identify and synthesize all empirical evidence that meets pre-defined criteria to answer a specific research question." Cochrane's current methodology is governed by the Cochrane Handbook for Systematic Reviews of Interventions (version 6.5, updated August 2024), which sets the standards for intervention reviews, and a separate handbook for Diagnostic Test Accuracy reviews.
The Institute of Medicine (now the National Academy of Medicine) published the foundational set of standards for systematic reviews in Finding What Works in Health Care: Standards for Systematic Reviews (National Academies Press, 2011), establishing 21 quality standards that cover the entire process from topic formulation through final reporting. These standards are the basis for how the Agency for Healthcare Research and Quality (AHRQ) evaluates its Evidence-Based Practice Center (EPC) systematic reviews.
The World Health Organization states that WHO guidelines are "informed by a comprehensive, systematic review of the relevant evidence on benefits and harms of an intervention or effects of exposure on priority outcomes." WHO uses GRADE certainty ratings to translate systematic review findings into guideline recommendations.
What all three frameworks share is an insistence on three non-negotiable elements: a pre-specified clinical question, a transparent and reproducible search, and a systematic approach to selecting, appraising, and synthesizing the available evidence. If any of these elements is absent, the review is not a systematic review, regardless of what it is called.
How a Clinical Systematic Review Differs from Other Evidence Synthesis Types
The term "systematic review" covers a family of review types, and not all of them answer clinical questions or follow the same methodology. Understanding exactly where a clinical systematic review sits in that family is essential before you begin, because the type of review you choose determines your registration obligations, your reporting standard, your eligible study designs, and what journal editors will expect.
A scoping review maps the breadth of a literature base to identify concepts, evidence types, and gaps, and does not require critical appraisal of included studies. A narrative review synthesizes evidence based on expert selection and interpretation without pre-specified methods. A meta-analysis is not a type of review at all; it is a statistical procedure that pools numerical results across studies and may or may not form part of a systematic review, depending on whether the evidence is suitable for pooling.
A clinical systematic review is specific in that it answers a focused, patient-centered question about the effectiveness, safety, accuracy, or prognosis of clinical interventions or tests, uses validated critical appraisal tools to assess study quality, and produces a GRADE-rated Summary of Findings table that directly informs clinical decisions. For a full breakdown of when each review type is appropriate and how to choose between them, see our guide on which type of evidence synthesis your question requires.
Table 1: How a Clinical Systematic Review Compares to Other Review Types
Feature | Clinical Systematic Review | Scoping Review | Narrative Review | Meta-Analysis | Rapid Review |
|---|---|---|---|---|---|
Purpose | Answer a focused clinical question by identifying, appraising, and synthesizing all eligible evidence | Map the breadth of a literature base; identify concepts, gaps, and evidence types | Provide expert overview of a topic; synthesize evidence without pre-specified methods | Statistical pooling of numerical results across studies (a component of a systematic review, not a review type) | Answer a focused question using simplified or restricted methods to reduce the time and resources required |
Pre-specified methods | Yes. Protocol required before searching begins. PRISMA-P for reporting. | Yes. Protocol recommended. JBI or Peters et al. methodology. | No. Source selection is at the author's discretion. | Yes, where conducted as part of a systematic review. | Partially. Some steps are streamlined or omitted compared to a full systematic review. |
Critical appraisal | Required. RoB 2, ROBINS-I V2, or QUADAS-2, depending on study design. | Not required. Scoping reviews map evidence without appraising quality. | Not required. No standard appraisal tool applied. | Required where conducted within a systematic review. | Recommended but may be limited to key domains only. |
GRADE required | Yes. A summary table of the findings, one per outcome, is required by most Tier 1 clinical journals. | No. Scoping reviews do not rate the certainty of evidence. | No. No formal certainty grading. | Yes, where conducted as part of a systematic review. | Recommended. May be abbreviated in rapid reviews with shorter timelines. |
PRISMA reporting | PRISMA 2020 (Page et al., BMJ, 2021). 27-item checklist. Flow diagram required. | PRISMA-ScR extension (Tricco et al., Ann Intern Med, 2018). | No standard reporting requirement. | PRISMA 2020. PRISMA-DTA extension for diagnostic meta-analyses. | PRISMA 2020 with transparent documentation of any streamlined steps. |
PROSPERO registration | Required before screening begins. Expected by BMJ, The Lancet, JAMA, and Annals. | Accepted. PROSPERO accepts scoping reviews as of 2022. | Not applicable. | Required where part of a systematic review. | Recommended. Some journals require it for rapid reviews. |
Evidence hierarchy level | Level I (Melnyk and Fineout-Overholt). The highest level of synthesized clinical evidence. | Not formally rated on the clinical evidence hierarchy. Provides evidence mapping, not evidence synthesis. | Level VII (expert opinion). Not systematic; susceptible to selection bias. | Level I when conducted within a systematic review. | Level I structure, but certainty is reduced by methodological streamlining. |
Typical timeline | 12–24 months from protocol to publication (Cochrane Handbook estimate). | 6–12 months. No critical appraisal or GRADE reduces the timeline. | Variable. No standardized process; expert-driven. | Adds 1–3 months to a completed systematic review data extraction phase. | 2–6 months. Streamlined methods reduce time but also evidential weight. |
Sources: Cochrane Handbook v6.5 (2024); PRISMA 2020 (Page et al., BMJ, 2021); PRISMA-ScR (Tricco et al., Ann Intern Med, 2018); Melnyk and Fineout-Overholt, Evidence-Based Practice in Nursing and Healthcare, 4th ed.
Five Clinical Question Types and the PICO Framework
Every clinical systematic review begins with a precisely formulated clinical question, and that question determines the methodology at every subsequent stage. Clinical questions fall into five categories:
Therapy and intervention: Does this treatment, drug, procedure, or public health intervention improve patient outcomes compared to the alternative? These questions use PICO (Population, Intervention, Comparison, Outcome) and are answered by randomized controlled trials, best synthesized using RoB 2 for bias assessment and DerSimonian-Laird random-effects models for meta-analysis.
Diagnostic accuracy: How accurately does this test, scale, or imaging modality identify a condition compared to a reference standard? These questions use the PICO framework, modified for diagnosis, and are answered using diagnostic accuracy studies, assessed using QUADAS-2.
Prognosis: What is the likely course of a condition over time, and what factors predict that course? These questions are answered by cohort studies and assessed using the ROBINS-I or QUIPS (Quality In Prognosis Studies) tools.
Etiology and harm: Does exposure to this factor increase the risk of a condition or adverse outcome? These are addressed by cohort and case-control studies, which are assessed using ROBINS-I.
Clinical practice guideline support: What is the full body of evidence on this clinical question to support a specific recommendation? These draw on all of the above question types and produce evidence-to-decision frameworks using GRADE.
The PICO framework is the core tool for translating a clinical question into a searchable, answerable structure. Each component of the PICO maps directly to database search terms and to the eligibility criteria that govern screening. For a step-by-step guide to building a clinical PICO and the common mistakes that make it unsearchable, see our complete guide to formulating your clinical PICOT question.
The 10-Stage Clinical Systematic Review Process
Stage 1: PROSPERO Registration
PROSPERO (the International Prospective Register of Systematic Reviews, hosted by the Centre for Reviews and Dissemination at the University of York) requires registration of the protocol before screening begins. The registration form has 22 mandatory fields, including the review question, PICO, eligibility criteria, databases to be searched, risk-of-bias tools, and planned synthesis methods. Most high-impact journals and Cochrane treat PROSPERO registration as a standard expectation. Registration cannot substitute for a protocol, but it creates a public, time-stamped record that reduces the risk of selective outcome reporting.
Stage 2: Protocol Development
The protocol follows PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols) and specifies every methodological decision in advance: the PICO, eligibility criteria for studies, databases to be searched, screening procedure, data extraction fields, risk-of-bias assessment methods, approach to synthesis (narrative or meta-analytic), and planned sensitivity and subgroup analyses. Decisions documented in the protocol cannot be changed after screening begins without being reported as post-hoc deviations.
Stage 3: Database Searching
The Cochrane MECIR (Methodological Expectations for Cochrane Intervention Reviews) standards require, at a minimum, searches of MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL). Bramer et al. (Systematic Reviews, 2017) found that single-database searching recovered as little as 85.9% of relevant studies even with the best individual database (EMBASE), while combining EMBASE and MEDLINE reached 92.8%. Restricting to one database is therefore a recognized methodological failure, not a pragmatic shortcut.
The complete database set for most clinical systematic reviews includes:
MEDLINE/PubMed (National Library of Medicine): mandatory for all clinical reviews
EMBASE (Elsevier): mandatory; stronger coverage of European literature, conference abstracts, and pharmacological studies than MEDLINE
Cochrane CENTRAL: the largest database of controlled clinical trials
CINAHL (EBSCO): for nursing, allied health, and clinical education topics
ClinicalTrials.gov and WHO ICTRP: to identify unpublished, ongoing, and recently completed trials and reduce publication bias
Grey literature: conference proceedings, government reports, theses, and technical documents
Search strategies must combine controlled vocabulary (MeSH in PubMed, Emtree in Embase) with free-text terms, use Boolean operators correctly, and avoid unjustified language or date restrictions. The PRISMA-S extension provides detailed guidance on reporting search strategies.
Stage 4: Title and Abstract Screening
All records from the database search are imported into a screening platform, most commonly Covidence or Rayyan, and deduplicated. Dual independent screening is then applied: two reviewers independently screen every title and abstract against the eligibility criteria and record a decision. Disagreements are resolved by discussion or a third reviewer. The proportion of records excluded at this stage is recorded for the PRISMA flow diagram.
Stage 5: Full-Text Review
Records that pass title and abstract screening proceed to full-text review, again conducted by two independent reviewers. Every excluded study must have a reason for exclusion documented, and the specific number excluded for each reason must be reported at submission. This is one of the most frequently flagged PRISMA 2020 items in peer review.
Stage 6: Data Extraction
Data is extracted from each included study into a piloted extraction form, again by two independent reviewers. Typical fields include: study design, population characteristics, intervention and comparator details, outcome measures and effect sizes, follow-up duration, funding source, and risk-of-bias ratings. Discrepancies between extractors are resolved before the synthesis stage.
Stage 7: Risk of Bias Assessment
The appropriate tool depends on the study design of the included studies:
RoB 2 (Cochrane Risk of Bias Tool for Randomized Trials; Sterne et al., BMJ, 2019): five domains covering randomization, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result. Judgment for each domain: low, some concerns, or high risk.
ROBINS-I (Risk Of Bias In Non-randomized Studies of Interventions; Sterne et al., BMJ, 2016): seven domains for observational studies.
QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies 2; Whiting et al., Ann Intern Med, 2011): four domains for diagnostic accuracy studies, covering patient selection, index test, reference standard, and flow and timing.
Risk-of-bias ratings feed directly into GRADE assessments and are typically presented in a summary table within the manuscript.
At the risk-of-bias, GRADE, or manuscript writing stage and need specialist input? |
|---|
Dual independent risk-of-bias assessment using RoB 2 or ROBINS-I V2, GRADE Summary of Findings tables, and a methods section that satisfies what JAMA, The Lancet, and the BMJ's methods editors expect are the three stages where most systematic review teams need specialist input. ScribeLab Writer's systematic review team covers all three as standalone services or as part of a full manuscript engagement. Submit your protocol details and target journal, and a PhD methodologist will respond within 2-4 hours. |
Stage 8: Meta-Analysis
Meta-analysis is performed when the included studies are sufficiently homogeneous in their populations, interventions, comparators, and outcome measures to allow statistical pooling. Key decisions include the choice of effect measure (risk ratio, odds ratio, mean difference, standardized mean difference, diagnostic odds ratio, or sensitivity/specificity), the statistical model (fixed-effect or random-effects), and the method for estimating between-study variance (DerSimonian-Laird is most common for random-effects models). Heterogeneity is assessed using the I² statistic, and publication bias is tested using funnel plots and Egger's regression test where ten or more studies are included. RevMan, Stata, and R (metafor package) are the most commonly used software environments.
Stage 9: GRADE Certainty Assessment
GRADE (Grading of Recommendations Assessment, Development and Evaluation) rates the certainty of evidence for each key outcome on a four-level scale: high, moderate, low, or very low. The assessment covers five domains that can downgrade certainty (risk of bias, inconsistency, indirectness, imprecision, and publication bias) and three domains that can upgrade it (large magnitude of effect, dose-response gradient, and plausible confounding). GRADE has been adopted by more than 110 organizations across 19 countries, including WHO, NICE, the American College of Physicians, and CDC. Certainty ratings are presented in a Summary of Findings table, which is required by most high-impact journals.
Stage 10: Manuscript Preparation and Submission
The manuscript is structured according to the reporting standard of the target journal, with the PRISMA 2020 checklist (27 items, with explanations and page references) submitted alongside it. Journal-specific requirements vary in terms of word limits and structural expectations: The Lancet requires a Research in Context panel; the BMJ requires a data-sharing statement; JAMA requires a presubmission inquiry for systematic reviews; and Annals of Internal Medicine treats systematic reviews as a defined submission category with specific formatting requirements.
PRISMA 2020: The Reporting Standard That Can Get Your Manuscript Returned
PRISMA 2020 (Page et al., BMJ, 2021) replaced the 2009 PRISMA statement and introduced changes that affect most manuscripts still following the older standard. The key updates require separate flow diagram pathways for database and non-database records, mandatory reporting of full search strategies for at least one database, explicit declaration of any automation tools used in screening or data extraction, and certainty ratings per outcome.
Most major clinical journals, including BMJ, The Lancet, Annals of Internal Medicine, and JAMA, either require PRISMA 2020 compliance or return manuscripts that follow the 2009 version. A systematic review submitted with an outdated flow diagram or a missing search strategy is typically flagged before it reaches substantive peer review. For a complete breakdown of all 27 items, what changed from 2009, and the most common reporting failures that cause desk rejection, see our complete PRISMA 2020 checklist guide.
Quality Appraisal Tools and When to Use Each
The choice of risk-of-bias tool is not a methodological preference; it is determined by the study designs of your included studies. Using the wrong tool, or omitting it entirely, is one of the most consistently cited reasons for desk rejection at methodology-focused journals.
Table 2: Risk of Bias Tools by Study Design
Study Design | Recommended Tool | Current Version | Domains | Output Scale | Cochrane Recommended |
|---|---|---|---|---|---|
Randomized controlled trials (RCTs) | RoB 2 (Cochrane Risk of Bias Tool for Randomized Trials) | RoB 2 (Sterne et al., BMJ, 2019). Applied per outcome, not per study. | 5: randomization process; deviations from intended interventions; missing outcome data; measurement of outcome; selection of reported result | Low / Some concerns / High risk of bias | Yes. Cochrane Handbook v6.5, Chapter 8. |
Non-randomized studies of interventions (cohort, registry, EHR studies) | ROBINS-I V2 (Risk Of Bias In Non-randomized Studies of Interventions) | V2 (November 2025 revision). Algorithm-based domain judgments. Explicit handling of immortal-time and prevalent-user bias. | 7: confounding; selection of participants; classification of interventions; deviations from intended interventions; missing data; measurement of outcomes; selection of reported result | Low / Moderate / Serious / Critical | Yes. Cochrane Handbook v6.5, Chapter 25. Use V2 for all reviews registered or submitted in 2026. |
Diagnostic accuracy studies | QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies 2) | QUADAS-2 (Whiting et al., Ann Intern Med, 2011). QUADAS-C extension available for comparative designs. | 4: patient selection; index test; reference standard; flow and timing | Low / High / Unclear risk of bias | Yes. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. |
Prognosis studies (cohort studies assessing disease course) | QUIPS (Quality In Prognosis Studies) | QUIPS (Hayden et al., Ann Intern Med, 2006; updated 2013). | 6: study participation; study attrition; prognostic factor measurement; outcome measurement; study confounding; statistical analysis and reporting | Low / Moderate / High risk of bias per domain | Yes, for prognosis reviews. Cochrane Prognosis Methods Group. |
Qualitative studies | CASP Qualitative Checklist (Critical Appraisal Skills Program) | CASP Qualitative Studies Checklist (2018 revision). Also: JBI Critical Appraisal Checklist for Qualitative Research. | 10 items covering research aims, design, recruitment, data collection, reflexivity, ethics, rigor, and findings | Yes / No / Can't tell per item. No composite score. | The CASP or JBI tool is recommended in the Cochrane Qualitative Methods Group guidance. |
Existing systematic reviews (included as evidence) | AMSTAR-2 (A Measurement Tool to Assess Systematic Reviews) | AMSTAR-2 (Shea et al., BMJ, 2017). Used in umbrella reviews and overviews of reviews. | 16 items (7 critical domains); covers protocol, search, study selection, data extraction, risk of bias, and meta-analytic methods | High / Moderate / Low / Critically Low confidence | Yes, for umbrella reviews and overviews of reviews. |
Non-randomized studies of exposures (etiological / harm studies) | ROBINS-E (Risk Of Bias In Non-randomized Studies of Exposures) | ROBINS-E (Higgins et al., 2021). Separate from ROBINS-I; designed for exposure rather than intervention effects. | 7 domains parallel to ROBINS-I but addressing exposure-specific bias sources, including time-varying confounding | Low / Moderate / Serious / Critical | Yes, for reviews of exposures and etiological questions. Available at riskofbias.info. |
Tool selection is determined by study design, not reviewer preference. Applying the wrong tool is grounds for desk rejection at methodology-focused journals. For reviews including multiple study designs, apply the appropriate tool for each design separately and report results by tool in the manuscript.
AMSTAR-2 deserves specific mention because it is used not to appraise primary studies but to evaluate the methodological quality of an existing systematic review, producing a confidence rating of high, moderate, low, or critically low. It is the appropriate tool when your clinical systematic review includes other reviews as evidence, or when an editor wants assurance that your review meets recognized quality thresholds.
Where Clinical Systematic Reviews Most Commonly Fail
Clinical systematic reviews fail at six points more frequently than any others, and most failures are preventable if they are anticipated at the protocol stage rather than discovered during peer review.
The search strategy is the most common structural failure. Restricting to one database, failing to search trial registries, omitting grey literature, or constructing a strategy that is not reproducible are all grounds for rejection at methodology-conscious journals. The standard set by Cochrane requires at minimum three databases plus trial registries, with full strategies reported and available.
PRISMA 2020 compliance failures, particularly the flow diagram, search strategy reporting, and automation declaration, remain the most commonly cited issues in peer review of clinical systematic reviews, even among researchers who are aware of PRISMA but who are using 2009-era templates.
GRADE omission or incomplete GRADE is the second most common cause of revision requests at journals like Annals of Internal Medicine and JAMA. A Summary of Findings table with certainty ratings is no longer optional for most Tier 1 clinical journals.
For a comprehensive analysis of the methodological failures that result in outright rejection versus major revision requests, and specific guidance on how to address each before submission, our guide on the most common reasons systematic reviews are rejected covers every failure point with evidence-based fixes.
Where Expert Support Makes the Difference
A clinical systematic review conducted to publication standards requires a combination of skills that most clinical researchers do not hold simultaneously: medical librarianship for the search strategy, biostatistics for the meta-analysis, methodological expertise for GRADE assessment, and medical writing for the manuscript. The reality is that most researchers conducting their first or second systematic review encounter a skills gap at one or more of these stages.
The stages where professional support is most commonly sought and most reliably improves outcomes are:
Search strategy development: Building a reproducible, peer-reviewed Boolean strategy across MEDLINE, EMBASE, CENTRAL, and registries requires specific technical training. A poorly constructed search is not a minor limitation; it compromises the validity of every subsequent stage. Medical librarians with systematic review training, or specialist search consultants, provide this as a standalone service and produce search strategies that meet Cochrane and MECIR standards. Our systematic review search strategy service builds and peer-reviews reproducible Boolean strategies across MEDLINE, EMBASE, CENTRAL, and the trial registries.
Dual screening and data extraction: The dual-independent requirement is non-negotiable for Cochrane and most high-impact journals. Research teams that lack a second trained reviewer frequently seek external support at this stage. Platforms such as Covidence are designed for team-based screening and provide an audit trail for reporting. Where a team lacks a second trained reviewer, our screening, data extraction, and risk-of-bias service provides the dual-independent second reviewer with documented inter-rater agreement.
Meta-analysis and statistical support: Random-effects modeling, heterogeneity analysis, subgroup and sensitivity analyses, and publication-bias testing require a biostatistician familiar with systematic review methods. This is particularly important when the included studies use different effect measures or when I² is high, requiring exploration rather than suppression. Our meta-analysis service delivers random-effects modeling, heterogeneity and subgroup analysis, and publication-bias testing with reproducible R or Stata code.
GRADE and Summary of Findings tables: GRADE is a structured judgment process that requires an understanding of the five downgrading domains and how to apply each to a specific body of evidence. Errors in GRADE that over- or under-rate certainty are frequently identified in peer review.
Manuscript writing and journal submission support: Structuring a clinical systematic review manuscript to meet the specific requirements of a target journal, covering word limits, PRISMA checklist, CONSORT/PRISMA-DTA extensions as applicable, data sharing, and research-in-context framing. This is a specialized writing task distinct from clinical writing or academic essay writing.
A clinical systematic review that satisfies every methodological requirement but fails on PRISMA 2020 compliance, GRADE presentation, or the methods section completeness that JAMA, The Lancet, and the BMJ's methods editors expect loses months of work at the desk rejection stage. ScribeLab Writer's systematic review team, led by credentialed researchers with published systematic reviews in the biomedical literature, works with research teams from protocol registration through to a submission-ready manuscript, covering search strategy, GRADE certainty ratings, and PRISMA 2020-compliant manuscript writing for reviews targeting Tier 1 and Tier 2 journals. Submit your protocol details and target journal through the inquiry form, and a member of the team will respond within 2-4 hours.
You May Also Find Useful
Frequently Asked Questions
What is the difference between a clinical systematic review and a Cochrane review?
A Cochrane review is a clinical systematic review produced through the Cochrane Collaboration's editorial process, which requires adherence to the Cochrane Handbook, MECIR standards, and Cochrane's internal peer review. Not all clinical systematic reviews are Cochrane reviews; most are published independently in clinical journals. However, the Cochrane Handbook sets the methodological standard that most high-impact journals benchmark against, so the distinction is one of governance and publication channel rather than fundamental methodology.
Do I need to register on PROSPERO before starting?
Yes, for all clinical systematic reviews intended for publication. PROSPERO registration is expected before screening begins and must be completed before any data is analyzed. Registration on PROSPERO after searching or screening has begun is recorded as retrospective registration, which is flagged in peer review. Most high-impact journals, including BMJ, The Lancet, and Annals of Internal Medicine, require PROSPERO registration at submission, though they do not universally mandate it across all review types.
How many databases do I need to search?
At minimum three for intervention reviews: MEDLINE, EMBASE, and Cochrane CENTRAL. For nursing and allied health topics, CINAHL is mandatory. For all clinical reviews, ClinicalTrials.gov and the WHO ICTRP should be searched to capture unpublished and ongoing trials. Bramer et al. (2017) demonstrated that combining EMBASE and MEDLINE achieved 92.8% recall, compared with 85.9% for EMBASE alone, underscoring that even the best single database misses a significant proportion of eligible studies.
Can I conduct a clinical systematic review without a meta-analysis?
Yes. A meta-analysis is appropriate only when the included studies are sufficiently homogeneous to pool statistically. When studies vary substantially in terms of population, intervention, or outcome measurement, the synthesis is either narrative or tabular. A clinical systematic review without meta-analysis is fully publishable in high-impact journals provided the synthesis method is justified, and the qualitative summary is rigorous.
How long does a clinical systematic review take?
The Cochrane Handbook estimates a typical range of 12 to 18 months from protocol to completion. Including manuscript preparation and journal peer review, the total time from PROSPERO registration to publication is commonly 18 to 24 months or longer. Reviews with narrow clinical questions and limited eligible literature can be completed faster. Reviews conducted by teams without prior systematic review experience or without a biostatistician consistently run longer.
What is GRADE and why do journals require it?
GRADE (Grading of Recommendations Assessment, Development and Evaluation) rates the certainty of a body of evidence for a specific outcome as high, moderate, low, or very low, based on five domains that may reduce certainty and three that may increase it. It has been adopted by more than 110 organizations across 19 countries, including the WHO, NICE, and the American College of Physicians. High-impact journals require GRADE because it forces explicit acknowledgment of the limitations of the evidence, prevents overclaiming, and makes review conclusions directly actionable in guideline development.
At what stage should I involve a biostatistician?
Before data extraction begins, not after. The statistical analysis plan, which specifies the effect measure, model selection, heterogeneity handling, subgroup analyses, and sensitivity analyses, should be finalized in the protocol. If a biostatistician is engaged after data extraction, they are constrained by decisions made without statistical input, increasing the risk of specification errors and post hoc analytical choices that reviewers will flag.
A clinical systematic review that reaches the manuscript stage with a complete search strategy, dual-independent screening, validated risk-of-bias assessments, and a GRADE Summary of Findings table for each outcome is in a position to survive peer review at a Tier 1 journal. One that reaches it without any of those elements is not. ScribeLab Writer's systematic review team, led by credentialed researchers with published systematic reviews in the biomedical literature, works with clinical research teams from PROSPERO registration through to a submission-ready manuscript. Submit your protocol details and target journal, and a PhD methodologist will respond within 2-4 hours.
